香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 表 明 概 不 就 因 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 依 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 北京市春立正達醫療器械股份有限公司 Beijing Chunlizhengda Medical Instruments Co., Ltd.* （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：1858） 有關截至2022年12月31日止年度的年報的 補充公告 根據上市規則附錄十六第32(4A)段，本 公 司 謹 此 提 供 有 關 其 價 值 佔 本 集 團 於 2022年12月31日總資產5%或以上的重大投資及其按公允價值計量且其變動計 入當期損益的金融資產（包 括 本 集 團 認 購 北 京 銀 行 及 中 國 建 設 銀 行 提 供 的 若 干 結構性存款產品（「結構性存款產品」））的 進 一 步 資 料。 繼本公司日期為2022年1月26 ...

Investment Strategy - Beijing Chunlizhengda Medical Instruments Co., Ltd. reported significant investments in structured deposit products, with a total investment amount of RMB 67,000,000 across various banks[2]. - The company has maintained a focus on utilizing idle fundraising for investment in structured deposits, enhancing liquidity management[3]. - The company continues to explore further investment opportunities in structured financial products to optimize asset allocation[4]. - The structured deposits are part of the company's broader financial strategy to ensure capital preservation and yield enhancement[4]. - The investment in structured deposit products is aimed at effectively utilizing temporarily idle funds raised from the public offering of A-shares, enhancing the overall capital return of the group[5]. Financial Performance - The annualized return for the structured deposits from Beijing Bank ranged from 1.35% to 1.6%, with actual returns reported at 3.2% for some products[2][3]. - The actual returns from structured deposits were reported as RMB 126.25 million, RMB 236.71 million, and RMB 196.03 million, reflecting positive investment outcomes[2][3]. - The company recorded investment income from structured deposit products of approximately RMB 6,748,000 and fair value changes of structured deposit products amounting to approximately RMB 9,491,000 as of December 31, 2022[5]. - As of December 31, 2022, the balance of structured deposit products was RMB 765,000,000, with a fair value of approximately RMB 767,728,000, accounting for about 23% of the company's total assets[5]. Cash Management - The company fully redeemed all structured deposits by the end of the reporting period, indicating effective cash management strategies[2][3]. - The company's core objectives include ensuring capital security and maintaining liquidity[5]. Banking Relationships - The company has established relationships with reputable banks, ensuring reliable investment channels for its financial products[4]. Monitoring and Future Objectives - The financial performance and investment strategies will be closely monitored to align with future growth objectives[4]. - The supplementary information provided does not affect other data disclosed in the 2022 annual report[5].

Financial Performance - Total revenue for Q1 2023 was ¥246,355,024.32, a decrease of 4.3% compared to ¥257,113,202.13 in Q1 2022[7] - The company's operating revenue for Q1 2023 was CNY 246,355,024.32, representing a decrease of 4.18% compared to the same period last year[35] - The net profit attributable to shareholders of the listed company was CNY 55,861,404.05, down 24.53% year-on-year[35] - The net profit for Q1 2023 was CNY 55,861,404.05, a decrease of 24.5% compared to CNY 74,021,366.53 in Q1 2022[44] - Operating profit for Q1 2023 was CNY 62,341,671.90, down 26.0% from CNY 84,279,091.21 in the same period last year[44] - Total profit for Q1 2023 reached CNY 62,225,078.79, a decline of 25.0% compared to CNY 82,950,225.44 in Q1 2022[44] Operating Costs and Expenses - Total operating costs increased to ¥183,535,965.29 in Q1 2023, up 7.1% from ¥170,342,269.72 in Q1 2022[7] - Research and development expenses for Q1 2023 were ¥33,270,315.66, slightly up from ¥33,114,231.75 in Q1 2022[7] - The net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 33.36% to CNY 49,607,213.75, primarily due to the impact of "volume-based procurement" and increased R&D investments[38] - The net cash flow from operating activities was negative at CNY -120,197,574.28, indicating increased cash outflows primarily due to higher R&D expenditures and raw material costs[35] Cash and Liquidity - Cash and cash equivalents at the end of Q1 2023 were ¥838,344,639.97, down from ¥1,025,826,965.44 at the end of Q1 2022[10] - The company reported a net decrease in cash and cash equivalents of ¥118,849,021.05 in Q1 2023[10] - Cash inflow from operating activities was CNY 212,802,558.95, slightly up from CNY 209,155,705.21 in Q1 2022, representing a growth of 1.3%[45] - Total cash flow from operating, investing, and financing activities indicates a challenging liquidity position for the company[56] - The company is focusing on improving cash flow management and reducing operational losses in future quarters[56] Shareholder Information - The number of common shareholders at the end of the reporting period was 5,766[1] - The largest shareholder, Shi Chunbao, holds 29.88% of shares, totaling 114,840,685 shares[2] - The total equity attributable to shareholders remained stable at ¥384,280,000.00[6] - The total equity attributable to shareholders of the listed company increased by 2.05% to CNY 2,775,561,183.72 compared to the end of the previous year[36] - The total equity attributable to shareholders of the parent company increased to CNY 2,775,561,183.72 from CNY 2,719,699,779.72, reflecting a growth of 2.1%[53] Assets and Liabilities - Total liabilities decreased to ¥615,416,974.31 in Q1 2023 from ¥690,066,911.19 in Q1 2022[6] - The company's total assets as of March 31, 2023, were CNY 3,391,412,670.08, a slight decrease of 0.54% from the end of the previous year[36] - The company's total liabilities decreased slightly, reflecting a stable financial position despite the challenges faced in the market[36] - The total liabilities and equity amounted to CNY 3,391,412,670.08, a slight decrease from CNY 3,409,766,690.91 in the previous year[53] Strategic Focus - The company emphasized its commitment to new product and technology development as part of its long-term strategic planning[38] - The management team is committed to strategic investments to enhance long-term growth despite current cash flow challenges[56]

Financial Performance - The company's operating revenue for Q1 2023 was RMB 246,355,024.32, representing a decrease of 4.18% compared to the same period last year[5] - Net profit attributable to shareholders for Q1 2023 was RMB 55,861,404.05, down 24.53% year-on-year[5] - The net profit after deducting non-recurring gains and losses was RMB 49,607,213.75, reflecting a decline of 33.36% compared to the previous year[5] - Basic and diluted earnings per share for Q1 2023 were both RMB 0.15, a decrease of 21.05% year-on-year[7] - The weighted average return on equity was 2.03%, down by 0.92 percentage points compared to the previous year[7] - The report indicates that the company is committed to enhancing its market position through strategic investments in R&D and product development[10] - The company reported a net profit margin decline due to increased operating costs, impacting overall profitability[16] - The net profit for Q1 2023 was CNY 55,861,404.05, a decrease of 24.5% compared to CNY 74,021,366.53 in Q1 2022[18] - Operating profit for Q1 2023 was CNY 62,341,671.90, down 26.0% from CNY 84,279,091.21 in the same period last year[18] Cash Flow - The net cash flow from operating activities was negative RMB 120,197,574.28, indicating a significant cash outflow[7] - The net cash flow from operating activities was not applicable, primarily due to increased R&D expenditures and higher cash outflows for raw material purchases influenced by "volume-based procurement"[10] - Cash flow from operating activities in Q1 2023 showed a net outflow of CNY 120,197,574.28, compared to a net outflow of CNY 20,120,816.00 in Q1 2022[21] - Cash inflow from investment activities in Q1 2023 was CNY 771,181,481.64, compared to CNY 904,215.33 in Q1 2022[21] - Cash outflow for the purchase of fixed assets and intangible assets in Q1 2023 was CNY 1,025,917.03, significantly lower than CNY 21,232,408.43 in Q1 2022[21] - The net increase in cash and cash equivalents was -$118,849,021.05, a notable decline from -$710,667,029.94 in the previous period[22] - The ending balance of cash and cash equivalents stood at $838,344,639.97, down from $1,025,826,965.44 in the previous period[22] Assets and Liabilities - Total assets at the end of Q1 2023 were RMB 3,391,412,670.08, a slight decrease of 0.54% from the end of the previous year[7] - Current assets totaled CNY 2,745,321,590.09, a slight decrease from CNY 2,779,088,982.86 in the previous year[14] - Non-current assets increased to CNY 646,091,079.99 from CNY 630,677,708.05 year-over-year[14] - Total liabilities decreased to CNY 615,416,974.31 from CNY 690,066,911.19 in the previous year[15] - Shareholders' equity rose to CNY 2,775,995,695.77, up from CNY 2,719,699,779.72 year-over-year[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 5,766, with the top ten shareholders holding significant stakes[11] - The largest shareholder, Shi Chunbao, held 29.88% of the shares, while the second-largest shareholder, Yue Shujun, held 24.84%[11] - The top ten shareholders include various institutional and individual investors, indicating a diverse ownership structure[12] - The company has not reported any significant changes in the relationships or agreements among the top shareholders[12] - The company has not disclosed any significant pledges or freezes on shares held by the top shareholders[12] Research and Development - Research and development expenses totaled RMB 33,270,315.66, accounting for 13.51% of operating revenue, an increase of 0.63 percentage points year-on-year[7] - The net profit attributable to shareholders, excluding non-recurring gains and losses, decreased by 33.36% due to the impact of "volume-based procurement" leading to a decline in terminal selling prices and increased R&D investments[10] - The company is focusing on long-term strategic planning, emphasizing the development of new products, technologies, and processes to drive innovation and product iteration[10] - The company has increased its R&D investment to support technological innovation and product upgrades[10] - Research and development expenses for Q1 2023 were CNY 33,270,315.66, slightly up from CNY 33,114,231.75 in Q1 2022[18] Operating Costs - Total operating costs increased to CNY 183,535,965.29, up 7.8% from CNY 170,342,269.72 in the previous year[16] - Operating costs included CNY 77,916,277.20 in operating expenses, which rose significantly from CNY 50,214,509.64 in Q1 2022[16] - The company recorded a decrease in sales expenses to CNY 64,965,051.80 in Q1 2023 from CNY 79,897,136.99 in Q1 2022, a reduction of 18.7%[18] Foreign Exchange and Accounting - The company recorded a foreign exchange gain of CNY 2,022,556.16 in Q1 2023, compared to a gain of CNY 1,695,561.64 in Q1 2022, indicating an increase of 19.2%[18] - The impact of exchange rate changes on cash and cash equivalents was -$218,020.84, reflecting currency fluctuations during the period[22] - The company did not apply new accounting standards or interpretations for the first quarter of 2023[23]

Financial Performance - In 2022, the company achieved operating revenue of RMB 1,201.60 million, representing a year-on-year growth of 8.43%[8]. - The net profit attributable to shareholders of the listed company was RMB 307.72 million, a decrease of 4.54% compared to the previous year[8]. - Basic earnings per share were RMB 0.80, reflecting a decline of 13.98% year-on-year[8]. - The company's operating revenue increased by 8.43% from approximately RMB 1,108.14 million in 2021 to approximately RMB 1,201.61 million in 2022, driven by growth in joint prosthesis sales and continuous sales increases in spinal and sports medicine products[17]. - Revenue from joint prosthesis products was approximately RMB 1,046.39 million, a slight increase of 1.05% from RMB 1,035.55 million in 2021; spinal products revenue surged by 70.14% to RMB 115.87 million; sports medicine products revenue skyrocketed by 927.01% to RMB 36.77 million[18]. - Gross profit rose by 6.90% from approximately RMB 854.54 million in 2021 to approximately RMB 913.53 million in 2022, while the gross profit margin decreased from 77.11% to 76.03% due to price reductions from the implementation of centralized procurement policies[19]. - The company's net profit decreased by 4.54% from approximately RMB 322.36 million in 2021 to approximately RMB 307.72 million in 2022, primarily due to price declines in products affected by centralized procurement policies[26]. - The total comprehensive income for 2022 was RMB 298,778,119.15, a decrease of approximately 7.5% from RMB 322,989,532.24 in the previous year[184]. Assets and Liabilities - The total assets of the company increased to RMB 3,409.77 million, up 13.67% from the end of the previous year[8]. - The company's current assets decreased by 44.88% from approximately RMB 1,736.49 million in 2021 to approximately RMB 957.19 million in 2022, mainly due to investments in financial products[26]. - The company's total current assets increased by 8.72% from approximately RMB 2,008.14 million in 2021 to approximately RMB 2,183.28 million in 2022[33]. - As of December 31, 2022, the company's accounts receivable balance was CNY 540.70 million, with a provision for bad debts amounting to CNY 51.95 million[166]. - The company's inventory balance as of December 31, 2022, was CNY 280.77 million, with a provision for inventory impairment of CNY 20.98 million[168]. - As of December 31, 2022, total liabilities amounted to RMB 690,066,911.19, an increase of 30.1% from RMB 530,579,974.97 in 2021[176]. - Current liabilities totaled RMB 595,804,539.93, up 35.5% from RMB 439,618,888.24 in the previous year[176]. Research and Development - The company has increased R&D investment, achieving significant results in laboratory construction and product development, with a total of 21 testing qualifications obtained by December 31, 2022[10]. - Research and development expenses increased by 54.84% from approximately RMB 104.84 million in 2021 to approximately RMB 162.34 million in 2022, accounting for 13.51% of total revenue, reflecting the company's focus on long-term strategic planning and innovation[23]. - Two products under the national key R&D project have entered the registration review stage, indicating progress in innovative product development[10]. - The company is committed to becoming a first-class international orthopedic innovation enterprise by enhancing R&D capabilities and brand influence[14]. Market Expansion and Strategy - The company successfully registered its products in eight countries, including Ukraine, South Korea, and Mexico, to expand its international market presence[9]. - The company accelerated the development of new products and expanded its market share amid ongoing pandemic challenges[7]. - The orthopedic implant market in China is expected to grow due to favorable factors such as an aging population and increased healthcare spending[16]. - The company aims to maintain its leading position in the domestic joint prosthesis market and continuously improve market share[12]. - The company plans to establish a professional sales team to enhance the development of various product lines, including joints, spine, sports medicine, and dental products[13]. - The company is expanding its market presence in Southeast Asia, targeting a 30% market share by 2025[56]. Corporate Governance and Compliance - The company has complied with all applicable principles and code provisions of the corporate governance code as of December 31, 2022[51]. - The board of directors consists of eight members, including four executive directors, one non-executive director, and three independent non-executive directors[100]. - The company is committed to maintaining high corporate governance standards and has complied with all applicable principles and provisions[99]. - The independent non-executive directors possess extensive experience in corporate governance, financial management, and medical engineering[102]. - The company has established a salary committee to review the compensation policy for all directors and senior management, considering operational performance and market practices[83]. Environmental and Social Responsibility - The company is committed to environmental sustainability by promoting energy conservation and encouraging the reuse of office supplies[86]. - The company has established a comprehensive environmental management system to mitigate its impact on natural resources[140]. - The company has committed to sustainable development and actively responds to national carbon neutrality policies[144]. - The company produced 6.905 tons of titanium waste in 2022, with a waste generation rate of 0.09 kg per RMB 10,000 of output[142]. - The total greenhouse gas emissions in 2022 included 19.37 tons of direct CO2 emissions and 3,216.9 tons of indirect CO2 emissions, with a CO2 emission rate of 0.0222 tons per RMB 10,000 of product[142]. Employee and Community Engagement - As of December 31, 2022, the company employed approximately 1,303 staff, with total salary and related costs amounting to RMB 193.41 million[43]. - The company has established multiple promotion pathways, including technical and management routes, to support employee development[151]. - The company has implemented a health check policy for new employees and provides annual health check cards for existing employees[148]. - The company continues to support the "Spring Sunshine Project," providing free internal fixation materials for joint replacement surgeries to impoverished patients, benefiting over 80 hospitals nationwide[158]. - The company has been actively involved in community investment, collaborating with various charitable organizations and conducting donation activities[158].

Financial Performance - The net profit attributable to the parent company for 2022 was RMB 307.72 million, with the parent company achieving a net profit of RMB 298.78 million[5]. - The proposed cash dividend distribution is RMB 3.13 per 10 shares, totaling RMB 120.06 million, which accounts for 39.02% of the net profit attributable to shareholders[6]. - The company reported a significant increase in revenue, reaching RMB 1.2 billion in 2022, representing a growth of 15% compared to the previous year[22]. - The company achieved operating revenue of ¥1,201,604,254.24 in 2022, representing a year-on-year growth of 8.43%[25]. - Net profit attributable to shareholders decreased by 4.54% to ¥307,719,145.65, while the net profit after deducting non-recurring gains and losses fell by 10.88% to ¥274,208,661.74[25]. - The net cash flow from operating activities was ¥41,007,526.40, a significant decline of 75.11% compared to the previous year[25]. - Basic and diluted earnings per share were both ¥0.80, reflecting a decrease of 13.98% year-on-year[24]. - The gross margin improved to 45% in 2022, up from 42% in 2021, reflecting better cost management and pricing strategies[22]. Research and Development - The company has invested RMB 50 million in R&D for innovative medical technologies, aiming to improve product offerings and patient outcomes[22]. - The company's R&D investment as a percentage of operating revenue increased to 13.51%, up by 4.05 percentage points from the previous year[24]. - The company reported a total R&D investment of approximately ¥162.34 million in 2022, a 54.84% increase from the previous year, representing 13.51% of total revenue[114]. - The number of R&D personnel increased to 399, representing 30.62% of the total workforce, up from 27.39% in the previous year[122]. - The average salary of R&D personnel rose to 12.41 million RMB, compared to 12.28 million RMB in the previous year[122]. - The company is focusing on R&D of new materials such as porous tantalum, magnesium alloy, and PEEK to enhance its product offerings[34]. - The company is actively pursuing innovation in emerging technologies, with ongoing research and development efforts in various new medical materials[81]. Market Expansion and Strategy - The company is expanding its market presence in Southeast Asia, targeting a 25% market share in the region by 2025[22]. - A strategic acquisition of a local competitor is in progress, which is anticipated to increase production capacity by 30%[22]. - The company plans to enhance its distribution network, aiming for a 15% increase in distribution points by the end of 2023[22]. - The company is actively expanding into overseas markets, which may be affected by international political and economic changes[134]. - The company is expanding its product offerings in sports medicine and dental fields, with new registrations for various medical devices, indicating a comprehensive approach to market expansion[110]. Product Development - New product development includes the launch of a next-generation orthopedic implant, expected to enhance market competitiveness and drive sales growth[22]. - The company is developing customized orthopedic implants, with several products in various stages of regulatory approval, including artificial ligaments and personalized hip and knee implants[118]. - The company is developing advanced customized joint prosthetics using China's national skeletal database and 3D reconstruction technology, which has a broader application range compared to existing customized products[79]. - The company has made significant progress in the development of 3D printing technologies for orthopedic implants, enhancing product quality and production efficiency[126]. - The company is in the design phase for a series of new biomedical materials, indicating a strong commitment to expanding its product offerings in the medical device market[81]. Corporate Governance - The board of directors consists of 8 members, including 3 independent non-executive directors, and held 15 meetings during the reporting period[184]. - The supervisory board is composed of 3 members, with at least one-third being employee representatives, and held 6 meetings during the reporting period[185]. - The company maintains independence in finance, personnel, assets, business, and organization, ensuring a complete business system and autonomous operational capability[186]. - The company has established a robust internal information disclosure management system, adhering to principles of truthfulness, accuracy, completeness, timeliness, and fairness[187]. - The company held its first A-share and H-share class shareholder meetings in 2022, approving various resolutions including the appointment of financial auditing institutions and the remuneration of directors[190]. Challenges and Risks - The company has outlined potential risks in its operations, which are detailed in the report[4]. - The company faced challenges from the "volume-based procurement" policy, leading to a decrease in product selling prices[25]. - The implementation of national "volume-based procurement" has led to a decrease in product prices, significantly squeezing profit margins[130]. - The company faced risks related to reliance on a single overseas supplier for core materials, which could impact production if supply is disrupted[129]. Financial Health - The company's cash and cash equivalents at the end of the reporting period amounted to ¥957.19 million, representing 28.07% of total assets, a decrease of 44.88% compared to the previous period[158]. - Accounts receivable increased by 22.13% to ¥488.75 million, accounting for 14.33% of total assets, primarily due to an expansion in sales scale[158]. - Inventory rose by 62.70% to ¥259.79 million, representing 7.62% of total assets, as the company increased product stock in response to market demand[158]. - The company’s accounts payable rose by 66.97% to ¥237.79 million, indicating an increase in business payables[158]. - The company’s tax payable increased by 65.78% to ¥53.55 million, attributed to the growth in business operations[158].

Financial Performance - The total revenue for the year ended December 31, 2022, was RMB 1,201,604,254.24, representing an increase of 8.4% compared to RMB 1,108,139,520.61 in 2021[6] - The operating profit for 2022 was RMB 328,908,764.68, a decrease of 10.5% from RMB 367,591,655.59 in the previous year[6] - The net profit attributable to shareholders for 2022 was RMB 1,136,732,358.10, up from RMB 908,847,424.37 in 2021, marking a growth of 25.1%[5] - The total profit for the year ended December 31, 2022, was RMB 336,879,766.43, a decrease of 8.3% from RMB 367,378,723.41 in 2021[7] - The net profit attributable to the parent company's shareholders for 2022 was RMB 307,719,145.65, down 4.0% from RMB 322,360,736.79 in 2021[9] - Basic earnings per share for 2022 were RMB 0.80, compared to RMB 0.93 in 2021, reflecting a decline of 14.0%[10] - The income tax expense for 2022 was RMB 29,160,620.78, significantly lower than RMB 45,017,986.62 in 2021, indicating a reduction of 35.3%[7] - The total comprehensive income attributable to the parent company's shareholders for 2022 was RMB 307,719,145.65, compared to RMB 322,360,736.79 in 2021, showing a decrease of 4.0%[10] Assets and Liabilities - The total assets as of December 31, 2022, amounted to RMB 3,409,766,690.91, compared to RMB 2,999,657,361.45 in 2021, indicating a growth of 13.7%[2] - The total liabilities as of December 31, 2022, were RMB 690,066,911.19, an increase from RMB 530,579,974.97 in 2021[4] - The total equity attributable to shareholders increased to RMB 2,719,699,779.72 in 2022 from RMB 2,469,077,386.48 in 2021, representing a growth of 10.1%[5] - The cash and cash equivalents as of December 31, 2022, were RMB 957,193,661.02, compared to RMB 767,727,534.25 in 2021, reflecting an increase of 24.7%[2] - As of December 31, 2022, the accounts receivable amounted to RMB 540,695,593.77, with a provision for bad debts of RMB 51,949,099.75, representing 9.61% of the total[14] - The total accounts payable as of December 31, 2022, was RMB 237,786,563.39, an increase of 67.0% from RMB 142,415,529.82 in 2021[3] Research and Development - Research and development expenses increased to RMB 162,340,798.73 in 2022, up from RMB 104,843,140.53 in 2021, reflecting a growth of 55%[6] - The company plans to continue investing in R&D to enhance product offerings and expand market presence in the coming years[6] - The company emphasizes R&D with a team of professionals, including PhDs and experienced personnel, ensuring continuous product innovation[36] - The company collaborates with clinical experts to ensure that its R&D products meet market demands and clinical practicality[36] - The company has initiated a large-scale clinical follow-up project involving over 300 hospitals in China, focusing on joint prosthetics[36] - The company obtained 21 testing qualifications by December 31, 2022, and its laboratory will undertake significant R&D projects for the nation, enhancing the safety and scientific design of new products[37] - The company led the application for a key national R&D project in 2020, focusing on the development and clinical application of multi-channel tantalum bone repair materials, which was approved by the Ministry of Science and Technology of the People's Republic of China[37] Market and Product Development - The orthopedic implant market in China is expected to grow due to factors such as an aging population, increasing medical expenditures, and improvements in public healthcare infrastructure[29] - The company has obtained 16 product registration certificates from the National Medical Products Administration in 2022, enhancing its product line and expanding its presence in the orthopedic field[31] - The company entered the oral field with registration certificates for orthodontic brackets, buccal tubes, and maxillofacial osteosynthesis systems, marking its official entry into this sector[33] - The company is developing an advanced customized joint prosthetic product using 3D reconstruction technology, targeting a broader range of patients and expected to yield higher profit margins[63] - The company anticipates continued growth in demand for its products, aligning with the expansion of the Chinese joint prosthetic market[62] - The company is focusing on the development of spinal products and sports medicine products alongside its joint prosthetic offerings[64] Corporate Governance and Shareholder Information - The company has adhered to all applicable principles and provisions of the corporate governance code as of December 31, 2022[75] - The board of directors proposed a final dividend of RMB 3.13 per 10 shares for the fiscal year ending December 31, 2022, compared to RMB 1.30 per 10 shares for the previous year[69] - The company will hold its annual general meeting on June 28, 2023, for shareholders to approve the proposed final dividend[70] - The company successfully listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on December 30, 2021, raising a total of RMB 1,145,538,680.00, netting RMB 1,067,128,292.23 after expenses[73] Employee and Talent Management - The company employed a total of approximately 1,303 employees as of December 31, 2022, with total salary and related costs amounting to approximately RMB 193.41 million[67] - The company has established an effective incentive mechanism to motivate employees and attract high-quality talent through a competitive compensation system[66] - The company will recruit more R&D talent and enhance collaboration with renowned medical institutions to strengthen its professional knowledge and competitiveness[64]

证券代码：688236 证券简称：春立医疗 公告编号：2023-007 北京市春立正达医疗器械股份有限公司 关于召开 2022 年度业绩暨现金分红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资者可于 2023 年 3 月 24 日(星期五)至 2023 年 03 月 30 日(星期四)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@clzd.com 进行提 问。公司将在说明会上对投资者普遍关注的问题进行回答。 北京市春立正达医疗器械股份有限公司（以下简称"公司"）将于 2022 年 3 月 31 日发布公司 2022 年度报告，为便于广大投资者更全面深入地了解公司 2022 年度经营成 果、财务状况，公司计划于 2023 年 03 月 31 日上午 10:00-11:30 举行 2022 年度业绩暨 现金分红说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以视频结合网络互动召开，公司将针对 2022 年度经营成果及财 务指标的具 ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥188,572,691.83, representing a decrease of 20.02% compared to the same period last year[8]. - Net profit attributable to shareholders for Q3 2022 was ¥52,725,036.03, an increase of 8.44% year-on-year[8]. - The net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 46.80% to ¥24,953,166.18 in Q3 2022[8]. - Total operating revenue for Q3 2022 was CNY 759,964,308.26, an increase from CNY 718,393,295.82 in Q3 2021, representing a growth of approximately 5.4%[38]. - Net profit for Q3 2022 reached CNY 209,707,532.63, compared to CNY 204,175,210.23 in Q3 2021, reflecting a slight increase of approximately 2.5%[41]. - The total comprehensive income for the period was CNY 209,707,532.63, compared to CNY 204,175,210.23 in the same period last year, reflecting an increase of approximately 2.5%[43]. - Basic and diluted earnings per share were both CNY 0.55, down from CNY 0.59 in the previous year, indicating a decrease of about 6.8%[43]. Research and Development - Research and development expenses totaled ¥32,724,564.79 in Q3 2022, accounting for 17.35% of operating revenue, an increase of 4.22 percentage points year-on-year[11]. - Research and development expenses for Q3 2022 amounted to CNY 105,014,400.73, significantly higher than CNY 65,183,009.37 in Q3 2021, marking an increase of around 61.1%[38]. - The company emphasized increased investment in R&D to address performance pressure and slow growth due to centralized procurement[16]. - The company aims to enhance its market share and competitiveness through continuous R&D investment and expansion of market channels[16]. Assets and Liabilities - Total assets at the end of Q3 2022 were ¥3,109,675,551.59, reflecting a 3.67% increase from the end of the previous year[11]. - The total assets as of Q3 2022 were CNY 3,109,675,551.59, compared to CNY 2,999,657,361.45 in Q3 2021, showing an increase of approximately 3.7%[34]. - Total liabilities for Q3 2022 were CNY 487,987,384.89, down from CNY 530,579,974.97 in Q3 2021, indicating a decrease of about 8.0%[34]. - The company's equity attributable to shareholders increased to CNY 2,621,688,166.70 in Q3 2022 from CNY 2,469,077,386.48 in Q3 2021, representing a growth of approximately 6.2%[34]. Cash Flow - The net cash flow from operating activities for the year-to-date was -¥76,368,941.72, a significant decline of 231.72%[11]. - Cash inflow from operating activities totaled CNY 675,604,729.35, an increase from CNY 635,612,963.26, representing a growth of approximately 6.3%[46]. - Cash outflow from operating activities was CNY 751,973,671.07, compared to CNY 577,635,870.48 in the previous year, showing an increase of about 30%[46]. - The net cash flow from operating activities was negative at CNY -76,368,941.72, contrasting with a positive CNY 57,977,092.78 in the same period last year[46]. - Cash inflow from investment activities was CNY 1,550,365,527.41, significantly higher than CNY 6,786,876.71 in the previous year[46]. - The net cash flow from investment activities was CNY -534,949,975.29, worsening from CNY -176,539,833.18 in the previous year[46]. - Cash outflow from financing activities was CNY 58,832,013.62, compared to CNY 1,685,045.25 in the previous year, indicating a substantial increase[46]. Shareholder Information - The total number of A-share shareholders at the end of the reporting period was 17,101, while H-share shareholders numbered 18[24]. - The number of shares held by the top ten shareholders accounted for a significant portion of the total shares, with the largest shareholder holding 29.88%[20]. - The total number of shares held by HKSCC NOMINEES LIMITED was 94,680,695, representing a substantial foreign investment presence[20]. Strategic Focus - The company aims to enhance its market share as a leading orthopedic enterprise by actively responding to national policies and expanding its marketing network[25]. - The company is focused on strategic layout for future growth, emphasizing the importance of tracking market dynamics and enhancing operational efficiency[25]. - The company plans to continue investing in new product development and market expansion strategies to drive future growth[41].